Ordinary shares, nominal value €0.12 per share
- Symbol
- NAMS
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 5.02 · 8-K
NewAmsterdam Pharma Company N.V.
NAMSNASDAQEQUITYCurrent
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On July 16, 2026, Douglas Kling notified NewAmsterdam Pharma Company N.V.…
Company context
NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company dedicated to building a new standard of care for people living with cardiometabolic and neurodegenerative diseases. The Company is advancing therapies designed to address a significant unmet need for safe, well-tolerated, and convenient treatment options that lower LDL-C while advancing innovation beyond a single marker to better address cardiovascular risk. In multiple Phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose, once-daily CETP inhibitor, alone and as a fixed-dose combination with ezetimibe, in patients at risk of cardiovascular disease with elevated LDL-C. Guided by its mission, the Company challenges convention with courage, translates deep biological insight into meaningful patient impact, and delivers with rigor, precision, and purpose.
Current securities
Registered securities in this filing
NewAmsterdam Pharma Company N.V. · 8-K · Filed 2026-07-22
Warrants to purchase ordinary shares
- Symbol
- NAMSW
- Exchange
- NASDAQ
- Classification
- WARRANT
- Status
- Current
Disclosure sections
Item 5.02Item 5.02 - Departure/Election of Directors
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On July 16, 2026, Douglas Kling notified NewAmsterdam Pharma Company N.V. (the “Company”) that he would resign as the Company’s Chief Operating Officer, effective August 14, 2026, to be appointed as the chief executive officer of another clinical-stage biotech company.
In connection with Mr. Kling’s departure, the Company expects to enter into a separation agreement. The Company also expects to enter into an advisor agreement with Mr. Kling pursuant to which he will provide transition and advisory services related to the Company’s PREVAIL clinical trial of obicetrapib and other clinical programs, subject to mutual agreement of terms. The material terms of any such separation agreement and advisor agreement will be disclosed in an amendment to this Current Report on Form 8-K.